Pharmacological strategies for muscular dystrophy
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) is a fatal, genetic disorder whose relentless progression underscores the urgency for developing a cure. Although Duchenne initiated clinical trials roughly 150 years ago, therapies for DMD remain supportive rather than curative. A paradigm shift towards developing rational therapeutic strategies occurred with identification of the DMD gene. Gene- and cell-based therapies designed to replace the missing gene and/or dystrophin protein have achieved varying degrees of success. However, pharmacological strategies not designed to replace dystrophin per se appear promising, and can circumvent many hurdles hampering gene- and cell-based therapy. Here, we will review present pharmacological strategies, in particular those dealing with functional substitution of dystrophin by utrophin and enhancing muscle progenitor commitment by myostatin blockade, with a view toward facilitating drug discovery for DMD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802
X chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988) · Cell · doi:10.1016/0092-8674(88)90383-2 · Cited by 1,538
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Membrane organization of the dystrophin-glycoprotein complex
Ervasti, J. M., & Campbell, K. P. (1991) · Cell · doi:10.1016/0092-8674(91)90035-w · Cited by 1,329
Research works printed but not linked: 3
- Duchenne, G. B. A. Recherches sur la paralysie musculaire pseudohypertrophique ou paralysie myo-sclerosique. Arch. Gen. Med. 11, 5–528 (1868).
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw–Hill, New York, 1994).
- Bonifati, M. D. et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23, 1344–1347 (2000). · DOI · Paper page
Cited by
Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle
Bellinger, A. M., Reiken, S., Carlson, C., Mongillo, M., Liu, X., Rothman, L., Matecki, S., Lacampagne, A., & Marks, A. R. (2009) · Nature Medicine · doi:10.1038/nm.1916 · Cited by 531
Acharyya, S., Villalta, S. A., Bakkar, N., Bupha-Intr, T., Janssen, P. M. L., Carathers, M., Li, Z.-W., Beg, A. A., Ghosh, S., Sahenk, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30556 · Cited by 438
Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse
Briguet, A., Courdier-Fruh, I., Foster, M., Meier, T., & Magyar, J. P. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.06.008 · Cited by 421
Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates
Camargo, F. D., Green, R., Capetenaki, Y., Jackson, K. A., & Goodell, M. A. (2003) · Nature Medicine · doi:10.1038/nm963 · Cited by 411
Nowak, K. J., & Davies, K. E. (2004) · EMBO reports · doi:10.1038/sj.embor.7400221 · Cited by 357
Self-citationLindsay, M. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1202 · Cited by 332
Myostatin propeptide‐mediated amelioration of dystrophic pathophysiology
Bogdanovich, S., Perkins, K. J., Krag, T. O. B., Whittemore, L.-A., & Khurana, T. S. (2005) · The FASEB Journal · doi:10.1096/fj.04-2796com · Cited by 242
Self-citationAnti‐TNFα (Remicade®) therapy protects dystrophic skeletal muscle from necrosis
Grounds, M. D., & Torrisi, J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1024com · Cited by 235
Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches
Fairclough, R. J., Wood, M. J., & Davies, K. E. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3460 · Cited by 229
Self-citationN ‐Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice
Whitehead, N. P., Pham, C., Gervasio, O. L., & Allen, D. G. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2007.148338 · Cited by 221
Rosmarin, A. G., Resendes, K. K., Yang, Z., McMillan, J. N., & Fleming, S. L. (2004) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2003.09.005 · Cited by 210
Pujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201
Bowman, C. L., Gottlieb, P. A., Suchyna, T. M., Murphy, Y. K., & Sachs, F. (2007) · Toxicon · doi:10.1016/j.toxicon.2006.09.030 · Cited by 192
Wu, W., Muchir, A., Shan, J., Bonne, G., & Worman, H. J. (2011) · Circulation · doi:10.1161/circulationaha.110.970673 · Cited by 190
Nakatani, M., Takehara, Y., Sugino, H., Matsumoto, M., Hashimoto, O., Hasegawa, Y., Murakami, T., Uezumi, A., Takeda, S., Noji, S., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-8673com · Cited by 187
Tinsley, J. M., Fairclough, R. J., Storer, R., Wilkes, F. J., Potter, A. C., Squire, S. E., Powell, D. S., Cozzoli, A., Capogrosso, R. F., Lambert, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019189 · Cited by 185
Self-citationLi, H., Mittal, A., Makonchuk, D. Y., Bhatnagar, S., & Kumar, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp191 · Cited by 179
Malignant Hyperthermia and Muscular Dystrophies
Gurnaney, H., Brown, A., & Litman, R. S. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181aa5cf6 · Cited by 166
Strength at the extracellular matrix–muscle interface
Grounds, M. D., Sorokin, L., & White, J. (2005) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/j.1600-0838.2005.00467.x · Cited by 167
Ljubicic, V., Miura, P., Burt, M., Boudreault, L., Khogali, S., Lunde, J. A., Renaud, J.-M., & Jasmin, B. J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr265 · Cited by 162
Contractile properties of EDL and soleus muscles of myostatin-deficient mice
Mendias, C. L., Marcin, J. E., Calerdon, D. R., & Faulkner, J. A. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00126.2006 · Cited by 162
Wallgren‐Pettersson, C., Sewry, C. A., Nowak, K. J., & Laing, N. G. (2011) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2011.10.004 · Cited by 184
Targeting RNA to treat neuromuscular disease
Muntoni, F., & Wood, M. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3459 · Cited by 171
Jarecki, J., Chen, X., Bernardino, A., Coovert, D. D., Whitney, M., Burghes, A. H. M., Stack, J. H., & Pollok, B. A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi205 · Cited by 158
Wasting mechanisms in muscular dystrophy
Shin, J. S., Tajrishi, M. M., Ogura, Y., & Kumar, A. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.001 · Cited by 161
Molecular and Cellular Determinants of Skeletal Muscle Atrophy and Hypertrophy
Sartorelli, V., & Fulco, M. (2004) · Science's STKE · doi:10.1126/stke.2442004re11 · Cited by 145
Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice
Amenta, A. R., Yilmaz, A., Bogdanovich, S., McKechnie, B. A., Abedi, M., Khurana, T. S., & Fallon, J. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013067108 · Cited by 159
Self-citationAcharyya, S., Sharma, S. M., Cheng, A. S. L., Ladner, K. J., He, W. A., Kline, W. O., Wang, H., Ostrowski, M. C., Huang, T. H. ‐., & Guttridge, D. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012479 · Cited by 151
Therapeutics for Duchenne muscular dystrophy: current approaches and future directions
Bogdanovich, S., Perkins, K. J., Krag, T. O. B., & Khurana, T. S. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0484-1 · Cited by 154
Self-citationStimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice
Chakkalakal, J. V., Harrison, M.-A., Carbonetto, S., Chin, E., Michel, R. N., & Jasmin, B. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddh037 · Cited by 136
Dorchies, O. M., Wagner, S., Patthey-Vuadens, O., Waldhauser, K., Buetler, T. M., Kučera, P., & Rüegg, U. T. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00425.2005 · Cited by 144
Banks, G. B., & Chamberlain, J. S. (2008) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(08)00609-1 · Cited by 155
Heregulin ameliorates the dystrophic phenotype in mdx mice
Krag, T. O. B., Bogdanovich, S., Jensen, C. J., Fischer, M. D., Hansen-Schwartz, J. A., Javazon, E. H., Flake, A. W., Edvinsson, L. I., & Khurana, T. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405972101 · Cited by 140
Self-citationShavlakadze, T., White, J. D., Hoh, J. F. Y., Rosenthal, N. A., & Grounds, M. D. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.026 · Cited by 124
Doran, P., Martin, G., Dowling, P., Jockusch, H., & Ohlendieck, K. (2006) · PROTEOMICS · doi:10.1002/pmic.200600082 · Cited by 123
Canine and feline models of human inherited muscle diseases
Shelton, G. D., & Engvall, E. (2005) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.10.019 · Cited by 127
Odom, G. L., Gregorevic, P., Allen, J. M., Finn, E. E., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.149 · Cited by 135
Bostick, B., Yue, Y., Long, C., & Duan, D. (2007) · Circulation Research · doi:10.1161/circresaha.107.162982 · Cited by 125
Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy
Girgenrath, M., Dominov, J. A., Kostek, C. A., & Miller, J. B. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22928 · Cited by 119
Winter, A., Higueruelo, A. P., Marsh, M., Sigurdardottir, A., Pitt, W. R., & Blundell, T. L. (2012) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583512000108 · Cited by 126
Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
Miura, P., & Jasmin, B. J. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.01.002 · Cited by 137
Streptomycin reduces stretch-induced membrane permeability in muscles from mdx mice
Whitehead, N. P., Streamer, M., Lusambili, L. I., Sachs, F., & Allen, D. G. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.07.024 · Cited by 125
Miura, P., Chakkalakal, J. V., Boudreault, L., Belanger, G., Hébert, R., Renaud, J.-M., & Jasmin, B. J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp431 · Cited by 124
Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts
Vandenburgh, H., Shansky, J., Benesch-Lee, F., Skelly, K., Spinazzola, J. M., Saponjian, Y., & Tseng, B. S. (2009) · The FASEB Journal · doi:10.1096/fj.09-134411 · Cited by 109
Systemic administration of L ‐arginine benefits mdx skeletal muscle function
Barton, E. R., Morris, L. D., Kawana, M., Bish, L. T., & Toursel, T. (2005) · Muscle & Nerve · doi:10.1002/mus.20425 · Cited by 124
Therapeutic approaches to muscular dystrophy
Goyenvalle, A., Seto, J. T., Davies, K. E., & Chamberlain, J. S. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr105 · Cited by 127
Self-citationSarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin
Li, D., Bareja, A., Judge, L., Yue, Y., Lai, Y., Fairclough, R., Davies, K. E., Chamberlain, J. S., & Duan, D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064808 · Cited by 106
Self-citationPerronnet, C., & Vaillend, C. (2010) · BioMed Research International · doi:10.1155/2010/849426 · Cited by 119
Reutenauer, J., Dorchies, O. M., Patthey-Vuadens, O., Vuagniaux, G., & Rüegg, U. T. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.285 · Cited by 117
-arginine improves dystrophic phenotype in mice
Voisin, V., Sebrié, C., Matecki, S., Yu, H., Gillet, B., Ramonatxo, M., Israël, M., & de la Porte, S. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.02.010 · Cited by 119
Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy
Fourcade, S., Ruíz, M., Guilera, C., Hahnen, E., Brichta, L., Naudí, A., Portero‐Otín, M., Dacremont, G., Cartier, N., Wanders, R. J. A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq082 · Cited by 109
13C NMR Metabolomics: Applications at Natural Abundance
Clendinen, C. S., Lee‐McMullen, B., Williams, C. M., Stupp, G. S., Vandenborne, K., Hahn, D. A., Walter, G. A., & Edison, A. S. (2014) · Analytical Chemistry · doi:10.1021/ac502346h · Cited by 112
Guess, M. G., Bjorkman, K. K., Harrison, B. C., & Leinwand, L. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118229 · Cited by 112
Viral-mediated gene therapy for the muscular dystrophies: Successes, limitations and recent advances
Odom, G. L., Gregorevic, P., & Chamberlain, J. S. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.09.007 · Cited by 114
Functional Substitution by TAT-Utrophin in Dystrophin-Deficient Mice
Sonnemann, K. J., Heun‐Johnson, H., Turner, A., Baltgalvis, K. A., Lowe, D. A., & Ervasti, J. M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000083 · Cited by 106
Current and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy
Berger, J., Pujol, A., Aubourg, P. R., & Forss‐Petter, S. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00393.x · Cited by 102
Definition of the unique human extraocular muscle allotype by expression profiling
Fischer, M. D., Budak, M. T., Bakay, M. A., Gorospe, J. R. M., Kjellgren, D., Domellöf, F. P., Hoffman, E. P., & Khurana, T. S. (2005) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2004 · Cited by 91
Self-citationDoran, P., Dowling, P., Lohan, J., McDonnell, K., Poetsch, S., & Ohlendieck, K. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04332.x · Cited by 102
Kumar, A., Bhatnagar, S., & Kumar, A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091176 · Cited by 93
Bartoli, M., Poupiot, J., Vulin, A., Fougerousse, F., Arandel, L., Danièle, N., Roudaut, C., Noulet, F., García, L., Danos, O., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302928 · Cited by 89
Fraysse, B., Liantonio, A., Cetrone, M., Burdi, R., Pierno, S., Frigeri, A., Pisoni, M., Camerino, C., & Luca, A. D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.06.002 · Cited by 82
Short interfering RNA‐mediated gene targeting in the zebrafish
Dodd, A. W., Chambers, S. P., & Love, D. R. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00129-2 · Cited by 81
Pathology is alleviated by doxycycline in a laminin‐α2–null model of congenital muscular dystrophy
Girgenrath, M., Beermann, M. L., Vishnudas, V. K., Homma, S. T., & Miller, J. B. (2008) · Annals of Neurology · doi:10.1002/ana.21523 · Cited by 76
Bogdanovich, S., McNally, E. M., & Khurana, T. S. (2008) · Muscle & Nerve · doi:10.1002/mus.20920 · Cited by 74
Self-citationMuscle ERRγ mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming
Matsakas, A., Yadav, V., Lorca, S., & Narkar, V. A. (2013) · The FASEB Journal · doi:10.1096/fj.13-228296 · Cited by 89
Doran, P., Wilton, S. D., Fletcher, S., & Ohlendieck, K. (2009) · PROTEOMICS · doi:10.1002/pmic.200800441 · Cited by 76
Dahiya, S., Givvimani, S., Bhatnagar, S., Qipshidze, N., Tyagi, S. C., & Kumar, A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101342 · Cited by 74
Moghadaszadeh, B., Albrechtsen, R., Guo, L. T., Zaik, M., Kawaguchi, N., Borup, R., Kronqvist, P., Schroder, H. D., Davies, K. E., Voït, T., et al. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg264 · Cited by 77
Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice
Li, D., Long, C., Yue, Y., & Duan, D. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp015 · Cited by 80
Crosstalk between Mitochondria and Cytoskeleton in Cardiac Cells
Kuznetsov, A. V., Javadov, S. A., Grimm, M. F., Margreiter, R., Ausserlechner, M. J., & Hagenbuchner, J. (2020) · Cells · doi:10.3390/cells9010222 · Cited by 75
Li, Z., Shelton, G. D., & Engvall, E. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62271-7 · Cited by 74
Doran, P., Dowling, P., Donoghue, P. M., Buffini, M., & Ohlendieck, K. (2006) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2006.01.007 · Cited by 74
Murphy, K. T., Ryall, J. G., Snell, S. M., Nair, L., Koopman, R., Krasney, P. A., Ibebunjo, C., Holden, K. S., Loria, P. M., Salatto, C. T., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090932 · Cited by 72
Jackson, M. F., Luong, D., Vang, D. D., Garikipati, D. K., Stanton, J. B., Nelson, O. L., & Rodgers, B. D. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0455 · Cited by 64
Chakkalakal, J. V., Michel, S. A., Chin, E. R., Michel, R. N., & Jasmin, B. J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl065 · Cited by 73
Harcourt, L. J., Holmes, A. G., Gregorevic, P., Schertzer, J. D., Stupka, N., Plant, D. R., & Lynch, G. S. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62333-4 · Cited by 63
Progress in therapy for Duchenne muscular dystrophy
Fairclough, R. J., Bareja, A., & Davies, K. E. (2011) · Experimental Physiology · doi:10.1113/expphysiol.2010.053025 · Cited by 74
Self-citationNakae, Y., Hirasaka, K., Goto, J., Nikawa, T., Shono, M., Yoshida, M., & Stoward, P. J. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0390-2 · Cited by 59
Cardiac and Respiratory Dysfunction in Duchenne Muscular Dystrophy and the Role of Second Messengers
Mosqueira, M., Zeiger, U., Förderer, M., Brinkmeier, H., & Fink, R. (2013) · Medicinal Research Reviews · doi:10.1002/med.21279 · Cited by 72
Miura, P., Thompson, J., Chakkalakal, J. V., Holčík, M., & Jasmin, B. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503994200 · Cited by 62
Anesthetic consideration for neuromuscular diseases
Katz, J. A., & Murphy, G. S. (2017) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000466 · Cited by 58
Translational Regulation of Utrophin by miRNAs
Basu, U., Lozynska, O., Moorwood, C., Patel, G., Wilton, S. D., & Khurana, T. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029376 · Cited by 60
Self-citationMichel, R. N., Chin, E. R., Chakkalakal, J. V., Eibl, J. K., & Jasmin, B. J. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h07-093 · Cited by 61
Impending therapies for Duchenne muscular dystrophy
Partridge, T. A. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834aa3f1 · Cited by 58
Ins and outs of therapy in limb girdle muscular dystrophies
Danièle, N., Richard, I., & Bartoli, M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.005 · Cited by 64
Therapeutic targeting of signaling pathways in muscular dystrophy
Bhatnagar, S., & Kumar, A. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0550-4 · Cited by 55
CAPON expression in skeletal muscle is regulated by position, repair, NOS activity, and dystrophy
Ségalat, L., Grisoni, K., Archer, J. D., Vargas, C., Bertrand, A., & Anderson, J. E. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.09.007 · Cited by 55
Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview.
Luca, A. D. (2012) · Europe PMC (PubMed Central) · Cited by 49
Guerron, A. D., Rawat, R., Sali, A., Spurney, C. F., Pistilli, E. E., Cha, H., Pandey, G. S., Gernapudi, R., Francia, D., Farajian, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011220 · Cited by 49
Welch, R. D., Billon, C., Valfort, A.-C., Burris, T. P., & Flaveny, C. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17496-7 · Cited by 51
The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy
Guiraud, S., Roblin, D., & Kay, D. E. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1438261 · Cited by 48
Invited review: Stem cells and muscle diseases: advances in cell therapy strategies
Négroni, E., Gidaro, T., Bigot, A., Butler-Browne, G. S., Mouly, V., & Trollet, C. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12198 · Cited by 55
Spengler, M., Adler, M., & Niemeyer, C. M. (2015) · The Analyst · doi:10.1039/c5an00822k · Cited by 51
Scotton, P., Bleckmann, D., Stebler, M., Sciandra, F., Brancaccio, A., Meier, T., Stetefeld, J., & Rüegg, M. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607887200 · Cited by 52
Regulation of the cardiac sodium channel Nav1.5 by utrophin in dystrophin-deficient mice
Albesa, M., Ogrodnik, J., Rougier, J., & Abriel, H. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq326 · Cited by 44
Utrophin Up-Regulation by an Artificial Transcription Factor in Transgenic Mice
Mattei, E., Corbi, N., Certo, M. G. D., Strimpakos, G., Severini, C., Onori, A., Desantis, A., Libri, V., Buontempo, S., Floridi, A., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000774 · Cited by 49
Self-citationMiura, P., Andrews, M., Holčı́k, M., & Jasmin, B. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002309 · Cited by 44
Current advances in cell therapy strategies for muscular dystrophies
Négroni, E., Vallese, D., Vilquin, J., Butler-Browne, G. S., Mouly, V., & Trollet, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.542748 · Cited by 48
Cellular Therapies for Muscular Dystrophies: Frustrations and Clinical Successes
Négroni, E., Bigot, A., Butler-Browne, G. S., Trollet, C., & Mouly, V. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.139 · Cited by 46
Diel, P. R., Schiffer, T., Geisler, S., Hertrampf, T., Mosler, S., Schulz, S., Wintgens, K. F., & Adler, M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.08.015 · Cited by 41
Metadata
- Authors
- Khurana, T. S., & Davies, K. E.
- Affiliations
- University of Pennsylvania (US)
- University of Oxford (GB)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-05-01
- Volume
- 2
- Issue
- 5
- Pages
- 379-390
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2090269652
- Cited by
- 225
- References
- 139
- Citations by year
- 2026: 1 · 2025: 4 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 9 · 2017: 4 · 2016: 5 · 2015: 12 · 2014: 12 · 2013: 10 · 2012: 11
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Muscular Dystrophy Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- Duchenne muscular dystrophy, pharmacotherapy, dystrophin, utrophin, muscle progenitor cells, gene therapy, cell therapy, drug discovery, muscle regeneration
- MeSH terms
- Animals, Calcium, Cytoskeletal Proteins, Disease Models, Animal, Drug Evaluation, Preclinical, Homeostasis, Humans, Membrane Proteins, Muscular Dystrophies, Promoter Regions, Genetic, Drug Design, Dystrophin, Utrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.